Clinical trial news

Two hands, a stethoscope, and a handful of oral medications frame a graph labeled

Higher-dose nusinersen may further improve SMA outcomes: Developer

A higher-dose regimen of nusinersen, currently up for approval in the U.S., may provide further benefits to people with spinal muscular atrophy (SMA) relative to the approved Spinraza regimen, according to its developer, Biogen. Nusinersen is marketed as Spinraza. The Phase 3 DEVOTE clinical trial (NCT04089566) part C showed…

Two hands, a stethoscope, and a handful of oral medications frame a graph labeled

Treatment with salanersen shows benefits for SMA children in trial

Interim results from a Phase 1 clinical trial show salanersen, Biogen’s treatment candidate for spinal muscular atrophy (SMA), slowed neurodegeneration, and improved motor function, in children with the genetic disease. The data also demonstrated that four of eight SMA children treated for at least one year attained new…